WHY IT MATTERS: Patients managing cancer-related appetite loss or chemotherapy-induced nerve pain may eventually have access to pharmaceutical-grade cannabinoid therapies developed specifically for those conditions rather than relying on general-use cannabis products. CLINICAL OVERVIEW: The endocannabinoid system continues to attract serious pharmaceutical investment, with companies developing targeted cannabinoid-based therapies for conditions like cancer-related anorexia and chemotherapy-induced peripheral neuropathy. These pipeline candidates represent a shift away from whole-plant preparations toward selective compounds designed to engage specific cannabinoid and related receptors with greater precision.